MANGOCEUTICALS, INC. (MGRX) - Dilution Analysis

10-Q filing | 16.5M shares outstanding

10-K filing | 17.0M shares outstanding

S-1/A filing: This S-1/A filing from Mangoceuticals, Inc. registers shares of common stock for resale by selling stockholders, including shares issuable upon exercise of warrants and already issued shares.

8-K filing: Mangoceuticals, Inc. entered into a securities purchase agreement with an institutional investor to issue and sell common shares and warrants in a registered direct offering and a concurrent private placement for gross proceeds of approximately $2.5 million. ($2.5M proceeds)

10-Q filing | 13.9M shares outstanding

8-K filing: Mangoceuticals, Inc. sold 709,677 shares of restricted common stock to five accredited investors for $1.55 per share, totaling $1,100,000. ($1.1M proceeds)

10-Q filing | 10.0M shares outstanding

8-K filing: Mangoceuticals, Inc. entered into a Mutual Rescission and Release Agreement with Navy Wharf, Ltd, terminating a Master Distribution Agreement and canceling 1,000,000 shares of the Company's restricted common stock previously issued to Navy Wharf. Additionally, a warrant holder exercised warrants to purchase 198,000 shares of common stock at $1.50 per share, for total proceeds of $297,000. ($0.3M proceeds)

8-K filing: Mango & Peaches Corp., a wholly-owned subsidiary of Mangoceuticals, Inc., filed a Certificate of Designations for its 6% Series B Convertible Cumulative Preferred Stock, designating 1,000,000 shares with specific dividend, liquidation, conversion, voting, protective, and redemption rights.

S-3 filing: The company intends to offer common stock, preferred stock, debt securities, warrants, or a combination of these securities for an aggregate initial offering price of up to $150 million.

8-K filing: Mangoceuticals, Inc. issued shares of common stock through warrant exercises and conversion of preferred stock, as well as sales under an Equity Line of Credit (ELOC). ($0.34M proceeds)

8-K filing: Mangoceuticals, Inc. issued 70,454 shares of common stock and warrants to purchase 35,227 shares of common stock for $116,249, and issued 120,000 shares of restricted common stock to Levo Healthcare Consulting, Inc. for marketing services. ($0.12M proceeds)

S-1 filing: Mangoceuticals, Inc. is registering 4,461,718 shares of common stock for resale by selling stockholders, including shares issuable upon exercise of warrants, conversion of Series B Convertible Preferred Stock, and conversion of a promissory note.

8-K filing: Mangoceuticals, Inc. entered into Rescission Agreements with ArcStone Securities, Smokeless Technology Corp., and Strategem Solutions Inc. to terminate previous agreements, resulting in the cancellation of shares and return of intellectual property. ($0.26M proceeds)

10-Q filing | 11.0M shares outstanding

8-K filing: Mangoceuticals, Inc. borrowed $100,000 from The Tiger Cub Trust, controlled by CEO Jacob D. Cohen, and issued 62,500 shares of restricted common stock to 1800 Diagonal Lending, LLC as part of a settlement agreement.

8-K filing: Mangoceuticals, Inc. entered into an Intellectual Property Purchase Agreement with Smokeless Technology Corp. for intellectual property related to oral pouches, issuing 1,600,000 shares of restricted common stock and agreeing to royalty payments, and entered into a Consulting Agreement with Strategem Solutions Inc., issuing 120,000 shares of common stock for consulting services.

8-K filing: Mangoceuticals, Inc. sold 100 shares of Series B Convertible Preferred Stock to an institutional accredited investor for $100,000 on April 11, 2025, and also borrowed $500,000 from Indigo Capital LP via a Promissory Note on April 15, 2025. ($0.1M proceeds)

8-K filing: Mangoceuticals, Inc. issued 256,666 shares of common stock upon conversion of Series B Convertible Preferred Stock and 333,333 shares of common stock upon conversion of debt owed to MAAB Global Ltd.

8-K filing: On March 28, 2025, holders of Mangoceuticals, Inc.'s Series B Convertible Preferred Stock converted shares into common stock of the Company pursuant to the terms of such Series B Convertible Preferred Stock, including the current conversion price of $1.50 per share.

8-K filing: Series B Convertible Preferred Stock was converted into common stock of the Company pursuant to the terms of such Series B Convertible Preferred Stock, including the current conversion price of $1.50 per share.

8-K filing: Mangoceuticals, Inc. issued 1,000,000 shares of restricted common stock to Navy Wharf, Ltd. pursuant to a Master Distribution Agreement.

10-K filing | 5.2M shares outstanding

8-K filing: Mangoceuticals, Inc. issued 200,000 shares of restricted common stock to 6330 Investment & Consulting Gmbh for consulting services and issued 80,000 shares upon warrant exercise at $1.50 per share. ($0.12M proceeds)

8-K filing: Mangoceuticals, Inc. executed several unregistered sales of equity securities, including the sale of restricted common stock, the issuance of common stock upon warrant exercises, and the conversion of preferred stock into common stock. ($0.71M proceeds)

8-K filing: Mangoceuticals, Inc. sold 70,000 shares of its restricted common stock to an accredited investor for $105,000, at a price of $1.50 per share, pursuant to a Subscription Agreement. ($0.11M proceeds)

8-K filing: Mangoceuticals, Inc. entered into a First Amendment to Payment Plan Letter Agreement with MAAB Global Ltd., allowing MAAB to convert $500,000 of debt into shares of the Company's common stock at a conversion price of $1.50 per share.

8-K filing: Mangoceuticals, Inc. converted $150,000 of debt owed to Mill End Capital Ltd. into 100,000 shares of restricted common stock at a conversion price of $1.50 per share. ($0.15M proceeds)

8-K filing: Mango & Peaches Corp., a wholly-owned subsidiary of Mangoceuticals, Inc., filed a Certificate of Designations establishing the designations, preferences, limitations, and relative rights of its Series A Super Majority Voting Preferred Stock, designating 100 shares of Series A Preferred Stock with special voting rights.

8-K filing: Mangoceuticals, Inc. entered into Securities Purchase Agreements with institutional accredited investors to sell Series B Convertible Preferred Stock and warrants to purchase common stock, closing the offering on January 6, 2025. ($0.9M proceeds)

8-K filing: Mangoceuticals, Inc. entered into Securities Purchase Agreements with institutional accredited investors, selling 250 shares of Series B Convertible Preferred Stock for $250,000 and warrants to purchase 330,000 shares of common stock, and 100 shares of Series B Preferred Stock for $100,000 and warrants to purchase 132,000 shares of common stock. ($0.35M proceeds)

8-K filing: Mangoceuticals, Inc. purchased patents from Greenfield Investments, Ltd for 515,000 shares of the company's restricted common stock on December 13, 2024.

8-K filing: Mangoceuticals, Inc. issued 40,000 shares of restricted common stock to Greentree Financial Group, Inc. as part of a service agreement.

10-Q filing | 2.5M shares outstanding

8-K filing: Mangoceuticals, Inc. sold 33,333 shares of common stock to Platinum Point Capital at $2.36 per share for total proceeds of $78,787 and the Purchaser converted 200 shares of Series B Preferred Stock into 93,299 shares of common stock. ($0.3M proceeds)

8-K filing: Stock split 1-for-15 | Outstanding: 29,905,803 → 1,993,720

8-K filing: Mangoceuticals, Inc. issued shares of common stock to Veritas Consulting Group, Inc., Levo Healthcare Consulting, Inc., and Luca Consulting, LLC for services, sold shares to Platinum Point Capital, and converted shares of Series B Preferred Stock into common stock. ($1.16M proceeds)

8-K filing: On September 26, 2024, the Company sold the Purchaser an additional 250 shares of Series B Preferred Stock for $250,000 in connection with a partial closing of the Fourth Closing. ($0.25M proceeds)

8-K filing: On August 22, 2024, the Company sold the Purchaser an additional 500 shares of Series B Preferred Stock for $500,000 in connection with a partial closing of the Fourth Closing. ($0.5M proceeds)

S-1 filing: This S-1 filing registers shares of common stock to be issued for resale by selling stockholders, including shares issuable upon exercise of warrants and conversion of Series B Convertible Preferred Stock. The company will not receive proceeds from the sale of shares by the selling stockholders, but may receive proceeds from the exercise of warrants.

10-Q filing | 29.9M shares outstanding

POS AM filing: This is a post-effective amendment to deregister 13,220,829 unsold shares of common stock previously registered under the Registration Statement that were issuable upon conversion of 500 shares of Series B Preferred Stock. As of July 25, 2024, all 500 shares of Series B Preferred Stock were fully converted.

8-K filing: Mangoceuticals, Inc. amended its Securities Purchase Agreement, completed a third closing involving the sale of Series B Preferred Stock and warrants, and provided updates on prior transactions involving the conversion of Series B Preferred Stock into Common Stock. ($1.0M proceeds)

8-K filing: Mangoceuticals, Inc. issued 192,308 shares of restricted common stock to a third party consultant for professional relations and consulting services, with additional shares to be issued later.

10-Q filing | 22.8M shares outstanding

S-1/A filing: The filing registers shares of common stock to permit the resale of these shares by the holders, with proceeds from the ELOC and warrant exercises to be used for general working capital.

8-K filing: Mangoceuticals, Inc. issued 980,000 shares of its newly designated 6% Series C Convertible Preferred Stock to Intramont Technologies, Inc. for $19,600,000 as part of a Patent Purchase Agreement. ($19.6M proceeds)

S-1 filing: This S-1 filing registers 30,014,286 shares of common stock for sale by selling stockholders, including shares issued as a commitment fee, shares issuable under an ELOC, shares issuable upon exercise of warrants, and shares issuable upon conversion of Series B Convertible Preferred Stock.

8-K filing: Mangoceuticals, Inc. entered into a Securities Purchase Agreement to sell Series B Convertible Preferred Stock and warrants to an institutional accredited investor for $1,500,000, and an Equity Purchase Agreement for the potential sale of common stock up to $25,000,000. ($1.0M proceeds)

10-K filing | 23.6M shares outstanding

8-K filing: Mangoceuticals, Inc. completed the sale of an additional 600,000 shares of common stock to underwriters on January 22, 2024, after the underwriters exercised their over-allotment option in full. Additionally, the company issued a warrant to the Representative for the purchase of 42,000 shares of its common stock.

8-K filing: Mangoceuticals, Inc. completed a public offering, selling 4,000,000 shares of its common stock at $0.30 per share, and issued a warrant to the Representative for 280,000 shares at an exercise price of $0.38. ($1.2M proceeds)

POS AM filing: Mangoceuticals, Inc. is offering 4,000,000 shares of its common stock at a public offering price of $0.30 per share.

POS AM filing: Mangoceuticals, Inc. is offering 4,000,000 shares of its common stock on a firm commitment basis.

S-1/A filing: Mangoceuticals, Inc. is offering 5,000,000 shares of its common stock on a firm commitment basis.

8-K filing: The company issued 100,000 shares of restricted common stock to Marius Pharmaceuticals, LLC in connection with a Marketing Agreement.

S-1 filing: Mangoceuticals, Inc. is offering 5,000,000 shares of its common stock on a firm commitment basis, with an over-allotment option for the underwriter to purchase up to 750,000 additional shares.

10-Q filing | 15.9M shares outstanding

8-K filing: Mangoceuticals, Inc. issued 75,000 shares of restricted common stock to Greentree Financial Group, Inc. as part of a service agreement.

10-Q filing | 15.8M shares outstanding

8-K filing: Mangoceuticals, Inc. issued 474,500 shares of common stock upon the exercise of warrants for $474,500 and agreed to issue 50,000 restricted shares of common stock to a consultant. ($0.47M proceeds)

10-Q filing | 16.0M shares outstanding

S-1/A filing: This S-1/A filing details a firm commitment initial public offering of Mangoceuticals, Inc. shares of common stock at $4.00 per share, along with the registration for resale of existing shares and shares issuable upon warrant exercise.

S-1/A filing: This is an S-1/A filing for an initial public offering of common stock by Mangoceuticals, Inc., subject to completion and Nasdaq approval, also registering the resale of existing shares and shares issuable upon warrant exercise.

S-1/A filing: This is a firm commitment initial public offering of shares of common stock of Mangoceuticals, Inc.

S-1/A filing: This is a firm commitment initial public offering of shares of common stock of Mangoceuticals, Inc.

S-1 filing: This is a firm commitment initial public offering of shares of common stock of Mangoceuticals, Inc.